is broad with many ancillary testing options. Given that some ancillary studies may be unnecessary, we evaluated the diagnostic utility of these studies to develop an evidence-based testing approach. Methods: We identified BM cases with a final diagnosis including eosinophilia. Pathology reports and ancillary testing results were reviewed: cytogenetics, immunohistochemistry (IHC) for tryptase/CD25/CD117, flow cytometry (T-cells, mast cells), FISH (BCR/ABL1, PDGFRA/ CHIC2, PDGFRB), and molecular testing (JAK2V617F, KITD816V, T-cell receptor gene rearrangement [TCRG] ). Results: Of 305 cases, 208 (68%) had isolated BM eosinophilia. Four (of 176) cases had a cytogenetic abnormality (+8, +8, Del20q (1) 
